Aurionpro Solutions receives DMRC order for Bhopal and Indore Metro projects

Aurionpro Solutions Limited has secured a fresh order from Delhi Metro Rail Corporation (DMRC) Limited to implement Automated Fare Collection (AFC) systems for the Bhopal and Indore Metro projects, strengthening its footprint across India’s metro rail network.

In a regulatory filing on Monday, January 12, Aurionpro said the multi-year contract, valued at around ₹150 crore, has been awarded as part of DMRC’s collaboration with Madhya Pradesh Metro Rail Corporation Limited. The project will involve supplying, implementing and maintaining open-loop EMV card- and QR-code-based AFC solutions for both metro systems.

Under the agreement, Aurionpro will deliver end-to-end AFC implementation followed by operations and maintenance support for five years. The systems are designed to enhance commuter convenience, improve operational efficiency and enable interoperability across the upcoming metro networks in Madhya Pradesh.

The company said its AFC solutions are built on open- and closed-loop EMV ticketing architecture, aligned with global payment standards and India’s Common Mobility Card (NCMC) norms. The offering is supported by Aurionpro’s in-house design and manufacturing capabilities under the “Made in India” framework.

Sanjay Bali, President – Tech Innovation Group at Aurionpro, said the engagement reinforces the company’s growing presence in India’s metro ecosystem and positions it strongly for additional opportunities in the rapidly evolving smart mobility space.

Last month, the company secured a multi-year transaction banking deal from a leading PSU bank to help it modernise its cash management infrastructure, covering payments, collections, liquidity management, virtual accounts, reconciliation, mandates and real-time reporting, using Aurionpro's iCashpro platform.

Following the announcement, shares of the company were trading 2.03% down at ₹1,034 as of 12.36 pm, up from intraday lows of ₹1,005 on Monday. The stock has dropped 36.96% in the past six months. 

Also Read: Alembic Pharma gets USFDA tentative approval for cancer treatment drug